Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRL017
MIFTS: 47

Prolymphocytic Leukemia

Categories: Blood diseases, Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Prolymphocytic Leukemia

About this section

MalaCards integrated aliases for Prolymphocytic Leukemia:

Name: Prolymphocytic Leukemia 12 74 15 71
Leukemia, Prolymphocytic 43
Leukemia Prolymphocytic 54

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1039
MeSH 43 D015463
NCIt 49 C3181
SNOMED-CT 67 10300002
UMLS 71 C0023486
Sources

Summaries for Prolymphocytic Leukemia

About this section
MalaCards based summary : Prolymphocytic Leukemia, also known as leukemia, prolymphocytic, is related to b cell prolymphocytic leukemia and t-cell prolymphocytic leukemia. An important gene associated with Prolymphocytic Leukemia is MTCP1 (Mature T Cell Proliferation 1), and among its related pathways/superpathways are IL-2 Pathway and Endometrial cancer. The drugs Cefepime and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are Increased human cytomegalovirus (HCMV) strain AD169 replication and Reduced mammosphere formation

Wikipedia : 74 Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell... more...

Sources

Related Diseases for Prolymphocytic Leukemia

About this section

Diseases related to Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 241)
# Related Disease Score Top Affiliating Genes
1 b cell prolymphocytic leukemia 33.3 ZAP70 TP53 MYC FCER2 CD5 CD38
2 t-cell prolymphocytic leukemia 32.5 TCL1A MYC MTCP1 JAK3 JAK1 HLA-S
3 adult lymphoma 30.4 MYC CD5 CD19
4 adult t-cell leukemia 30.4 TP53 MYC JAK3 CD7
5 anemia, autoimmune hemolytic 30.4 ZAP70 CD52 CD5 CD19
6 ataxia-telangiectasia 30.2 TP53 TCL1A MTCP1 ATM ABL1
7 pancytopenia 30.1 TP53 CD7 CD5 CD19
8 lymphoblastic lymphoma 30.0 TP53 MYC CD7 CD5
9 rare tumor 29.9 FCER2 CR2
10 plasmacytoma 29.9 MYC CD5 CD38 CCND1
11 sezary's disease 29.8 MYC JAK3 CD7 CD52 CD5
12 hairy cell leukemia 29.8 TP53 CD52 CD5 CD38 CCND1 ADA
13 leukemia 29.8 TP53 TCL1A MYC JAK3 JAK1 CCND1
14 leukemia, chronic lymphocytic 2 29.8 ZAP70 FCER2 CD5 CD38 ATM
15 richter's syndrome 29.8 ZAP70 TP53 MYC CD5 CD38 ATM
16 precursor t-cell acute lymphoblastic leukemia 29.7 TCL1A MYC CD7 ABL1
17 t-cell adult acute lymphocytic leukemia 29.6 TP53 JAK3 CD7 CD52 CD5
18 diffuse large b-cell lymphoma 29.4 TP53 TCL1A MYC CD5 CD38 CD19
19 t-cell leukemia 29.3 TP53 TCL1A MYC MTCP1 JAK3 JAK1
20 mantle cell lymphoma 29.1 TP53 TCL1A MYC CD52 CD5 CD19
21 peripheral t-cell lymphoma 29.1 TP53 TCL1A CD5 CD38 CD19 CCND1
22 lymphocytic leukemia 28.9 ZAP70 TP53 MYC FCER2 CD52 CD5
23 cll/sll 28.8 ZAP70 TP53 CD5 CD38 CD19 CCND1
24 lymphoma 28.5 TP53 TCL1A MYC CR2 CD5 CD38
25 lymphoma, mucosa-associated lymphoid type 28.5 ZAP70 TP53 MYC CR2 CD5 CD19
26 b-cell lymphoma 28.3 ZAP70 TP53 TCL1A MYC FCER2 CR2
27 leukemia, acute lymphoblastic 28.1 ZAP70 JAK3 JAK1 CD7 CD5 CD38
28 leukemia, acute myeloid 27.2 TP53 MYC JAK3 JAK1 CD7 CD5
29 burkitt lymphoma 26.9 TP53 TCL1A MYC JAK3 JAK1 FCER2
30 leukemia, chronic lymphocytic 26.8 ZAP70 TP53 TCL1A MYC FCER2 CR2
31 lymphoma, non-hodgkin, familial 26.7 TP53 TCL1A MYC FCER2 CR2 CD7
32 splenic manifestation of prolymphocytic leukemia 12.4
33 splenomegaly 10.8
34 chromosomal triplication 10.6
35 lymphoproliferative syndrome 10.6
36 lymphoma aids related 10.6 TCL1A MYC
37 thrombocytopenia 10.5
38 telangiectasis 10.4
39 ataxia and polyneuropathy, adult-onset 10.4
40 listeria meningitis 10.4 CD52 ADA
41 invasive malignant thymoma 10.4 CD38 CD19
42 anal carcinoma in situ 10.4 TP53 MYC
43 parapsoriasis 10.4 CD7 CD5
44 monoclonal paraproteinemia 10.3 CD38 CD19
45 graft-versus-host disease 10.3
46 neutropenia 10.3
47 refractory hematologic cancer 10.3 CD38 CD19
48 maxillary sinus adenocarcinoma 10.3 TP53 ATM
49 immunodeficiency 19 10.3 ZAP70 JAK3 ADA
50 plasmablastic lymphoma 10.3 MYC CD38

Graphical network of the top 20 diseases related to Prolymphocytic Leukemia:



Diseases related to Prolymphocytic Leukemia
Sources

Symptoms & Phenotypes for Prolymphocytic Leukemia

About this section

GenomeRNAi Phenotypes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.35 ABL1 ATM JAK1 JAK3 ZAP70
2 Reduced mammosphere formation GR00396-S 9.23 ATM CCND1 CD5 CD52 CD7 JAK3
3 Decreased viability in HMC1.1 cells GR00105-A-0 9.16 JAK1 JAK3

MGI Mouse Phenotypes related to Prolymphocytic Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 ABCB4 ABL1 ADA ATM CCND1 CD19
2 hematopoietic system MP:0005397 10.16 ABCB4 ABL1 ADA ATM CCND1 CD19
3 cardiovascular system MP:0005385 10.13 ABCB4 ABL1 ADA ATM CCND1 CD19
4 endocrine/exocrine gland MP:0005379 10.1 ABCB4 ABL1 ADA ATM CCND1 CD38
5 immune system MP:0005387 10.06 ABCB4 ABL1 ADA ATM CCND1 CD19
6 digestive/alimentary MP:0005381 10.02 ABCB4 ABL1 ADA CCND1 CD19 FCER2
7 liver/biliary system MP:0005370 9.5 ABCB4 ABL1 ADA CD19 JAK1 MYC
8 normal MP:0002873 9.28 ABL1 ADA CCND1 CD19 CD5 JAK1
Sources

Drugs & Therapeutics for Prolymphocytic Leukemia

About this section

Drugs for Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ofloxacin Approved Phase 3 82419-36-1 4583
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
6
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
7
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
8
Ondansetron Approved Phase 3 99614-02-5 4595
9
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
10
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
11
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
12
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 23925 27284
13
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
14
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
15
Dalteparin Approved Phase 3 9005-49-6
16
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
17
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
20
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Topoisomerase Inhibitors Phase 3
23 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
24 Anesthetics, Dissociative Phase 3
25 Vidarabine Phosphate Phase 3
26 Analgesics Phase 3
27 Etoposide phosphate Phase 2, Phase 3
28 Liver Extracts Phase 3
29 Cola Phase 3
30 Antipsychotic Agents Phase 3
31 Antiemetics Phase 3
32 Central Nervous System Depressants Phase 3
33 Gastrointestinal Agents Phase 3
34 Tranquilizing Agents Phase 3
35 Analgesics, Opioid Phase 3
36 Neurotransmitter Agents Phase 3
37 Autonomic Agents Phase 3
38 Psychotropic Drugs Phase 3
39 Antipruritics Phase 3
40 Anti-Anxiety Agents Phase 3
41 Serotonin Agents Phase 3
42 Serotonin Antagonists Phase 3
43 Hematinics Phase 3
44 Epoetin alfa Phase 3 113427-24-0
45 Fibrinolytic Agents Phase 3
46 calcium heparin Phase 3
47 Heparin, Low-Molecular-Weight Phase 3
48 Narcotics Phase 3
49 Excitatory Amino Acid Antagonists Phase 3
50 Excitatory Amino Acids Phase 3

Interventional clinical trials:

(show top 50) (show all 203)
# Name Status NCT ID Phase Drugs
1 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
2 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
4 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
5 Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
6 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
7 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
8 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
9 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
10 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
11 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
12 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
13 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
14 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
15 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
16 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
17 Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02851589 Phase 1, Phase 2
18 Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02819583 Phase 1, Phase 2
19 PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02892695 Phase 1, Phase 2
20 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
21 Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma Unknown status NCT01735604 Phase 1, Phase 2
22 A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies Unknown status NCT01092026 Phase 1, Phase 2
23 Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning for Patients With Chronic Lymphocytic Leukemia - A Multi-center Trial Completed NCT00060424 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
24 Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
25 Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
26 A Multicenter, Open-label, Single Arm Study of Weekly Alvocidib in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising From CLL Completed NCT00464633 Phase 2 alvocidib
27 A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT01244906 Phase 2
28 Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL Completed NCT01515176 Phase 1, Phase 2 Dinaciclib
29 Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
30 A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial Completed NCT01251575 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
31 Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells Completed NCT00006252 Phase 2 fludarabine phosphate;Cyclophosphamide;G-CSF
32 A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL) Completed NCT01419691 Phase 2 auranofin
33 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
34 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
35 Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation Completed NCT00053196 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol
36 Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial Completed NCT00104858 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
37 Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients With CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed NCT00546793 Phase 1, Phase 2
38 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
39 Trial of Immune Reconstitution With Activated T-Cells in Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT02530515 Phase 2
40 Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen Completed NCT00309842 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
41 An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
42 Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) in Newly Diagnosed and Relapsed Indolent Lymphoproliferative Malignancies Completed NCT00005626 Phase 2 Irinotecan
43 A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia Completed NCT00452374 Phase 1, Phase 2 Cytarabine;Fludarabine;Oxaliplatin;Rituximab
44 A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia, Aggressive, Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia Completed NCT00472849 Phase 1, Phase 2 Oxaliplatin;Fludarabine;Cytarabine;Rituximab;Pegfilgrastim
45 Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) Completed NCT00364286 Phase 2 Dasatinib (BMS-354825)
46 Phase II Study of High Dose Cyclophosphamide and Rituximab in Low Grade and Mantle Cell Lymphoma Completed NCT00278161 Phase 2 Cyclophosphamide
47 Phase II Multicenter Trial Of Pentostatin and Rituximab In Patients With Previously Treated and Untreated Low Grade B-Cell Non-Hodgkin's Lymphoma (NHL) Including Chronic Lymphocytic Leukemia (CLL) Completed NCT00026351 Phase 2 pentostatin
48 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
49 Low Intensity Preparative Regimen Followed by HLA-Matched, Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in Older Adults Completed NCT00001637 Phase 2
50 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2

Search NIH Clinical Center for Prolymphocytic Leukemia

Cochrane evidence based reviews: leukemia, prolymphocytic

Sources

Genetic Tests for Prolymphocytic Leukemia

About this section
Sources

Anatomical Context for Prolymphocytic Leukemia

About this section

MalaCards organs/tissues related to Prolymphocytic Leukemia:

40
T Cells, B Cells, Bone, Bone Marrow, Myeloid, Breast, Liver
Sources

Publications for Prolymphocytic Leukemia

About this section

Articles related to Prolymphocytic Leukemia:

(show top 50) (show all 823)
# Title Authors PMID Year
1
[CD5-positive B-cell prolymphocytic leukemia]. 54 61
20134145 2010
2
Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. 54 61
19278963 2009
3
Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia. 54 61
18073348 2008
4
High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. 54 61
17890451 2008
5
IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). 54 61
16642047 2006
6
D cyclins in CD5+ B-cell lymphoproliferative disorders: cyclin D1 and cyclin D2 identify diagnostic groups and cyclin D1 correlates with ZAP-70 expression in chronic lymphocytic leukemia. 54 61
16393687 2006
7
Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. 54 61
15459205 2004
8
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. 54 61
15133473 2004
9
ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. 54 61
12149228 2002
10
Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif. 54 61
11821961 2002
11
Structure of murine Tcl1 at 2.5 A resolution and implications for the TCL oncogene family. 54 61
11679718 2001
12
TCL1 is activated by chromosomal rearrangement or by hypomethylation. 54 61
11241786 2001
13
Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. 54 61
10786666 2000
14
Aberrant splicing of the ATM gene associated with shortening of the intronic mononucleotide tract in human colon tumor cell lines: a novel mutation target of microsatellite instability. 54 61
10738255 2000
15
Role of TCL1 and ALL1 in human leukemias and development. 54 61
10197596 1999
16
Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. 54 61
9657733 1998
17
Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL. 54 61
9622061 1998
18
Inactivation of the ATM gene in T-cell prolymphocytic leukemias. 54 61
9573030 1998
19
Solution structure of the recombinant human oncoprotein p13MTCP1. 54 61
9691281 1998
20
Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology. 54 61
9519406 1998
21
Alternative origin of p13MTCP1-encoding transcripts in mature T-cell proliferations with t(X;14) translocations. 54 61
9315101 1997
22
Perforin-positive leukemic cell infiltration in the aortic tissue of a patient with T-cell prolymphocytic leukemia. 54 61
8971584 1996
23
Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. 54 61
8634440 1996
24
Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32). 54 61
7497446 1995
25
B-cell prolymphocytic leukemia expressing CD13 antigen. 54 61
7524729 1994
26
Burkitt-like mutations in the c-myc gene locus in prolymphocytic leukemia. 54 61
8182948 1994
27
Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. 54 61
8172823 1994
28
Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2'-deoxycoformycin. 54 61
1528066 1992
29
Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. 54 61
2323839 1990
30
Purine metabolism enzymes and immunological phenotype in chronic B-cell malignancies: chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia. 54 61
2125699 1990
31
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. 61
31677197 2020
32
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. 61
32012154 2020
33
Advances and Perspectives in the Treatment of T-PLL. 61
32034661 2020
34
First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). 61
31566032 2020
35
Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab. 61
31960738 2020
36
Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia. 61
31965420 2020
37
Initial treatment of B-cell prolymphocytic leukemia with ibrutinib. 61
31951033 2020
38
Direct Targeting Options for STAT3 and STAT5 in Cancer. 61
31817042 2019
39
Bilateral tonsillar infiltration of T-cell prolymphocytic leukemia. 61
31788291 2019
40
Auer Rod-Like Inclusions in B-Cell Prolymphocytic Leukemia 61
30238921 2019
41
B-cell prolymphocytic leukemia has 3 subsets. 61
31751477 2019
42
Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. 61
31527074 2019
43
Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. 61
31698446 2019
44
B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax. 61
31713446 2019
45
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL. 61
31766351 2019
46
Pretransplant adaptive NKG2C+ NK cells protect against cytomegalovirus infection in kidney transplant recipients. 61
31612635 2019
47
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. 61
31292114 2019
48
Generalized pruritic dark papules in a patient with T-cell prolymphocytic leukemia - a clinicopathological challenge. 61
31515798 2019
49
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). 61
30664723 2019
50
Genomics of LGL leukemia and select other rare leukemia/lymphomas. 61
31585620 2019
Sources

Variations for Prolymphocytic Leukemia

About this section
Sources

Expression for Prolymphocytic Leukemia

About this section
Search GEO for disease gene expression data for Prolymphocytic Leukemia.
Sources

Pathways for Prolymphocytic Leukemia

About this section

Pathways related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
IL-2 Pathway 63
Show member pathways
 13.2 TP53 MYC JAK3 JAK1 FCER2 CR2
2
Endometrial cancer 36
Show member pathways
 12.84 TP53 MYC JAK1 CCND1 ABL1
3
Pathways in cancer 36
12.82 TP53 MYC JAK3 JAK1 CCND1 ABL1
4
PI3K-Akt signaling pathway 36
Show member pathways
 12.81 TP53 TCL1A MYC MTCP1 JAK3 JAK1
5
Measles 36
Show member pathways
 12.71 TP53 MYC JAK3 JAK1 FCER2 CR2
6
ErbB signaling pathway 1 36
Show member pathways
 12.6 TP53 MYC JAK1 CCND1 ABL1
7
NF-kappaB Signaling 4
12.55 ZAP70 JAK3 JAK1 CD38 CD19
8
MicroRNAs in cancer 36
12.52 TP53 MYC CCND1 ATM ABL1
9
Prolactin Signaling Pathway 1 36
Show member pathways
 12.45 ZAP70 MYC JAK1 CCND1
10
DNA Damage Response 1
Show member pathways
 12.37 TP53 MYC CCND1 ATM ABL1
11
Cell cycle 1 36
12.36 TP53 MYC CCND1 ATM ABL1
12
Development IGF-1 receptor signaling 22
Show member pathways
 12.36 TP53 MYC JAK3 JAK1 FCER2 CCND1
13
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.32 MYC JAK3 JAK1 CCND1
14
Viral carcinogenesis 36
12.27 TP53 JAK3 JAK1 CCND1
15
Human T-cell leukemia virus 1 infection 36
12.27 TP53 MYC JAK3 JAK1 CCND1 ATM
16
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.25 TP53 MYC JAK1 ATM ABL1
17
p53 Signaling 63
Show member pathways
 12.23 TP53 CCND1 ATM ABL1
18
Colorectal Cancer Metastasis 63
12.17 TP53 MYC JAK1 CCND1
19
Cellular senescence (KEGG) 36
12.15 TP53 MYC CCND1 ATM
20
Integrated Breast Cancer Pathway 1
12.03 TP53 MYC JAK1 CCND1 ATM ABL1
21
DNA Damage Response (only ATM dependent) 1
11.97 TP53 MYC CCND1 ATM ABL1
22
Small cell lung cancer 36
11.83 TP53 MYC CCND1
23
Retinoblastoma (RB) in Cancer 1
11.83 TP53 MYC CCND1 ABL1
24
ATM Pathway 63
Show member pathways
 11.8 TP53 ATM ABL1
25
C-MYB transcription factor network 1
11.75 MYC CCND1 ADA
26
Bladder cancer 36 1
11.72 TP53 MYC CCND1
27
Regulation of Telomerase 1
11.7 MYC CCND1 ATM ABL1
28
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.68 MYC JAK3 JAK1
29
Pathways Affected in Adenoid Cystic Carcinoma 1
11.67 TP53 MYC ATM
30
IL4-mediated signaling events 1
11.64 JAK3 JAK1 FCER2
31
p53 pathway 1
11.61 TP53 ATM ABL1
32
Hepatitis C and Hepatocellular Carcinoma 1
11.58 TP53 MYC JAK1 CCND1
33
Integrated Cancer Pathway 1
11.51 TP53 MYC JAK1 ATM
34
IL-7 Signaling Pathway 1
Show member pathways
 11.5 MYC JAK3 JAK1 CCND1
35
Interleukin-4 and 13 signaling 65
11.49 TP53 MYC JAK3 JAK1 FCER2 CCND1
36
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.47 TP53 MYC CCND1 ATM
37
B Cell Development Pathways 64
11.38 FCER2 CR2 CD5 CD38 CD19
38
Primary immunodeficiency 36
11.36 ZAP70 JAK3 CD19 ADA
39
IL-10 Pathway 63
11.34 MYC JAK1 CCND1
40
GADD45 Pathway 63
11.29 TP53 CCND1 ATM
41
miRNAs involved in DNA damage response 1
11.25 TP53 MYC CCND1 ATM ABL1
42
Telomere Extension by Telomerase 63
Show member pathways
 11.18 MYC JAK3 JAK1
43
Inhibition of Ribosome Biogenesis by p14(ARF) 63
11.11 TP53 MYC ABL1
44
Hematopoietic cell lineage 36
11.1 FCER2 CR2 CD7 CD5 CD38 CD19
45
TP53 Network 1
Show member pathways
 11.08 TP53 MYC ATM ABL1
Sources

GO Terms for Prolymphocytic Leukemia

About this section

Cellular components related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.7 TP53 MYC CD52 CD38 CD19 ATM
2 membrane GO:0016020 9.53 ZAP70 TP53 MYC JAK3 JAK1 FCER2
3 protein-containing complex GO:0032991 9.43 TP53 TCL1A MYC MTCP1 CD19 ABL1

Biological processes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.01 TP53 TCL1A MYC CD38 ADA
2 cellular response to DNA damage stimulus GO:0006974 9.98 TP53 MYC CCND1 ATM ABL1
3 immune system process GO:0002376 9.91 ZAP70 JAK3 CR2 CD7 CD19 ATM
4 protein phosphorylation GO:0006468 9.85 ZAP70 JAK3 JAK1 CCND1 ATM ABL1
5 positive regulation of response to DNA damage stimulus GO:2001022 9.62 MYC ATM
6 regulation of cell cycle GO:0051726 9.62 TP53 CCND1 ATM ABL1
7 regulation of cellular senescence GO:2000772 9.61 TP53 ABL1
8 replicative senescence GO:0090399 9.6 TP53 ATM
9 interleukin-15-mediated signaling pathway GO:0035723 9.59 JAK3 JAK1
10 interleukin-2-mediated signaling pathway GO:0038110 9.58 JAK3 JAK1
11 T cell activation GO:0042110 9.58 ZAP70 CD7 ADA
12 positive regulation of protein oligomerization GO:0032461 9.57 TP53 TCL1A
13 positive regulation of alpha-beta T cell differentiation GO:0046638 9.56 ZAP70 ADA
14 peptidyl-tyrosine phosphorylation GO:0018108 9.56 ZAP70 JAK3 JAK1 ABL1
15 interleukin-9-mediated signaling pathway GO:0038113 9.55 JAK3 JAK1
16 response to vitamin E GO:0033197 9.54 CCND1 ADA
17 interleukin-21-mediated signaling pathway GO:0038114 9.52 JAK3 JAK1
18 mitotic G1 DNA damage checkpoint GO:0031571 9.51 TP53 CCND1
19 DNA damage induced protein phosphorylation GO:0006975 9.49 ATM ABL1
20 negative regulation of thymocyte apoptotic process GO:0070244 9.48 JAK3 ADA
21 B cell proliferation involved in immune response GO:0002322 9.46 CD19 ABL1
22 cell cycle arrest GO:0007050 9.46 TP53 MYC ATM ABL1
23 response to drug GO:0042493 9.35 TP53 MYC CD38 CCND1 ADA
24 cytokine-mediated signaling pathway GO:0019221 9.1 TP53 MYC JAK3 JAK1 FCER2 CCND1

Molecular functions related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.73 ZAP70 JAK3 JAK1 CCND1 ATM ABL1
2 protein kinase activity GO:0004672 9.63 ZAP70 JAK3 JAK1 CCND1 ATM ABL1
3 protein phosphatase binding GO:0019903 9.5 TP53 JAK3 JAK1
4 protein tyrosine kinase activity GO:0004713 9.26 ZAP70 JAK3 JAK1 ABL1
5 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.92 ZAP70 JAK3 JAK1 ABL1
Sources

Sources for Prolymphocytic Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....